Company Overview and News

 
Syrah Resources Ltd. 2018 Q3 - Results - Earnings Call Slides

2018-10-11 seekingalpha
The following slide deck was published by Syrah Resources Ltd. in conjunction with their 2018 Q3 earnings call.
SRHYY SYR SYAAF

3
Markets Live: ASX closes higher on healthcare gains

2018-10-10 theage.com.au
Australian shares ended a turbulent trading session higher on Wednesday as healthcare stocks rebounded from two days of losses.
WOPEF RIO BLT RMYHY RIO LYSCF SRHYY MAYNF RTPPF MYX SYR RTNTF RMSYF BHPBF LMHA WPL LMHB WOPEY MYPHY SYAAF BHP RIO RHC LYSDY BBL BHP BHPLF LM

3
Markets Live: ASX closes higher on healthcare gains

2018-10-10 watoday.com.au
Australian shares ended a turbulent trading session higher on Wednesday as healthcare stocks rebounded from two days of losses.
WOPEF RIO BLT RMYHY RIO LYSCF SRHYY MAYNF RTPPF MYX SYR RTNTF RMSYF BHPBF LMHA WPL LMHB WOPEY MYPHY SYAAF BHP RIO RHC LYSDY BBL BHP BHPLF LM

3
Markets Live: ASX closes higher on healthcare gains

2018-10-10 smh.com.au
Australian shares ended a turbulent trading session higher on Wednesday as healthcare stocks rebounded from two days of losses.
WOPEF RIO BLT RMYHY RIO LYSCF SRHYY MAYNF RTPPF MYX SYR RTNTF RMSYF BHPBF LMHA WPL LMHB WOPEY MYPHY SYAAF BHP RIO RHC LYSDY BBL BHP BHPLF LM

 
Syrah Resources Balama project catches fire

2018-10-04 australianmining.com.au
A fire has occurred at Syrah Resources’ Balama graphite operation, less than a week since the project received approvals from the Mozambique Government.
SRHYY SYR SYAAF

 
Mustang Resources produces high-grade vanadium concentrate from Caula ore

2018-10-03 proactiveinvestors.com.au
Mustang Resources Ltd (ASX:MUS) has produced high-grade vanadium concentrate in initial bench-scale metallurgical test work on ore from its Caula Vanadium-Graphite Project in Mozambique.
MUS SRHYY SYR SYAAF

14
Markets Live: Banks rally following interim report

2018-09-28 theage.com.au
Australian shares closed the quarter on a high note this week, as the banks rallied on the release of the royal commission's interim report.
BGX WOPEF BLT LYSCF SRHYY BGLF OGFGY OISHF BEPTF SYR OSH WBC OISHY BHPBF WEBNF BX SDA WPL WBK BCHEY WOPEY BGB SYAAF BPT WBC BHP LYSDY BBL BHP OGFGF BHPLF ORG

14
Markets Live: Banks rally following interim report

2018-09-28 watoday.com.au
Australian shares closed the quarter on a high note this week, as the banks rallied on the release of the royal commission's interim report.
BGX WOPEF BLT LYSCF SRHYY BGLF OGFGY OISHF BEPTF SYR OSH WBC OISHY BHPBF WEBNF BX SDA WPL WBK BCHEY WOPEY BGB SYAAF BPT WBC BHP LYSDY BBL BHP OGFGF BHPLF ORG

14
Markets Live: Banks rally following interim report

2018-09-28 smh.com.au
Australian shares closed the quarter on a high note this week, as the banks rallied on the release of the royal commission's interim report.
BGX WOPEF BLT LYSCF SRHYY BGLF OGFGY OISHF BEPTF SYR OSH WBC OISHY BHPBF WEBNF BX SDA WPL WBK BCHEY WOPEY BGB SYAAF BPT WBC BHP LYSDY BBL BHP OGFGF BHPLF ORG

2
Markets Live: ASX closes modestly higher

2018-09-26 watoday.com.au
Australian shares closed marginally higher on Wednesday, as the resource stocks continued to be weighed by the major financials ahead of the royal commission's interim report.
TMP WOPEF RIO BLT RIO SNMYF API SRHYY AGLNF IAG MDBPF OGFGY OISHF AGLNY RTPPF SUN SYR RTNTF ILKAY OSH IAUGY OISHY BHPBF ILKAF SNMCY WPL WHC ILU WOPEY SYAAF MDBKY MPL IAUGF BHP RIO BBL BHP OGFGF WAM BHPLF ORG

20
Graphite Miners News For The Month Of September 2018

2018-09-26 seekingalpha - 2
Graphite company news - Several large successful capital raises for graphite companies. Triton Minerals lands Shandong Tianye as a cornerstone investor.
GRXXF URA SRHYY BKR BSSMF LMRMF URLNF URRE EAF ZEYYF GPHEF RNU GPHOF GRAPHITE BSM LLG APMFD NSRC KBBRF CYLYF AMVMF WKT IMYSY FMS GRPH TON ZENYF DNI BKT MUS IMYSF DMNKF SYR 509488 LMR NGPHF TLG LEMIF WWR ZEN FSRCY SYAAF KNL ECORF SVM NSRCF MGPHF URI FCSMF CZSVF

 
Mustang Resources eyes first cash flow from world-class vanadium-graphite project in 2019

2018-09-17 proactiveinvestors.com.au
Mustang Resources Ltd (ASX:MUS) is fast-tracking its world-class Caula Vanadium-Graphite Project in Mozambique, with first cash flows targeted for H2 of 2019 from trial mining operations.
MUS SRHYY SYR SYAAF

2
Heavyweight finance stocks send ASX to 12 week low

2018-09-13 theage.com.au
The Australian sharemarket closed at a 12-week low on Thursday, as the royal commission continued to weigh on the finance sector.
PMCUF NCMGF WOPEF NCM RIO BLT RIO SRHYY SNDFY BEPTF RTPPF PME SYR RTNTF SFR WNARF WSA BHPBF WPL BCHEY WOPEY SYAAF BPT TNE NCMGY SFRRF BHP RIO BBL BHP BHPLF

2
Heavyweight finance stocks send ASX to 12 week low

2018-09-13 smh.com.au
The Australian sharemarket closed at a 12-week low on Thursday, as the royal commission continued to weigh on the finance sector.
PMCUF NCMGF WOPEF NCM RIO BLT RIO SRHYY SNDFY BEPTF RTPPF PME SYR RTNTF SFR WNARF WSA BHPBF WPL BCHEY WOPEY SYAAF BPT TNE NCMGY SFRRF BHP RIO BBL BHP BHPLF

 
Mustang Resources drilling extends graphite vanadium resource

2018-09-06 proactiveinvestors.com.au
Mustang Resources Ltd (ASX:MUS) has completed, ahead of schedule, its feasibility study drilling program on the Caula Vanadium-Graphite Project in Mozambique.
MUS SRHYY SYR SYAAF

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...